Le français est une traduction alpha automatisée. Pour le texte officiel, consultez la version anglaise.

Comparer

Comparer des captures archivées

Cette vue met en évidence des différences de texte entre deux captures archivées. Elle n’interprète pas le sens et ne fournit pas de directives.

Changements descriptifs seulement

Cette comparaison met en évidence des changements de texte entre des captures archivées. Elle n’interprète pas le changement et ne fournit pas d’avis médical. Pour des recommandations à jour, consultez toujours le site officiel de la source.

Besoin de citer cette comparaison? Voir /cite.

Capture précédente

List of Drugs for an Urgent Public Health Need - Canada.ca

18 avr. 2025

legacy-hc-2025-04-21

ID 207873

Capture suivante

List of Drugs for an Urgent Public Health Need - Canada.ca

2 janv. 2026

hc-20260101

ID 428658

updated2 sections changed; 1 added; 1 removed
2 sections modifiées1 ajoutées1 retirées+22 / -9 lignesVariation: 21%
---
+++
@@ -4,7 +4,7 @@
A public health official notification allows a listed drug to be imported into Canada and sold in the notifying jurisdiction for a period of 1 year. If a notification has not been renewed by a public health official within one year of the initial notification, the drug will no longer be eligible for importation and sale. Drugs may also be removed from the List at any time at the Minister's discretion.
A drug is only eligible for importation and sale if all columns on the List are populated, including columns located under the "For Information Purposes" subheading.
(
-PDF Version - 141 KB, 1 page
+PDF Version - 211 KB, 1 page
)
List of Drugs for an Urgent Public Health Need
Brand name
@@ -15,10 +15,8 @@
Foreign identifying code or number
For Information Purposes
Foreign regulatory authority/ Foreign country
-Canadian jurisdiction notifying for the drug
-/Date of notification by a public health official
-Urgent public health need -
-Applicable Foreign Authorised Indication (Intended use or purpose of the drug)
+Canadian jurisdiction notifying for the drug/Date of notification by a public health official
+Urgent public health need - Applicable Foreign Authorised Indication (Intended use or purpose of the drug)
Priftin
Rifapentine
Tablet
@@ -46,12 +44,28 @@
1
Important foreign identified risk information-see footnote below
Public Health Agency of Canada - for use in all jurisdictions/
-January 15, 2025
+November 28, 2025
Tuberculosis crisis –
For the treatment of latent tuberculosis infection (LTBI) caused by
Mycobacterium tuberculosis
in combination with isoniazid in patients at high risk of progression to TB disease.
-Footnotes
+Rifampin for Injection, USP
+Rifampin
+Powder
+600 mg/vial
+Intravenous
+63323-351-20
+FDA/USA
+Footnote
+1
+Important foreign identified risk information-see footnote below
+Public Health Agency of Canada – for use in all jurisdictions/
+June 30, 2025
+Tuberculosis crisis –
+Rifampin for injection is indicated in the treatment of all forms of tuberculosis, including the initial treatment and re-treatment of tuberculosis when the drug cannot be taken by mouth. It is also indicated for the treatment of asymptomatic carriers of
+Neisseria meningitidis
+to eliminate meningococci from the nasopharynx.
+Footnote
Footnote 1
Foreign Identified Risk: Rifapentine has been identified by the US FDA as one of the drugs that contains nitrosamine impurities. For more information, please visit the US FDA website:
https://www.fda.gov/drugs/drug-safety-and-availability/fda-works-mitigate-shortages-rifampin-and-rifapentine-after-manufacturers-find-nitrosamine
@@ -63,5 +77,4 @@
Notification of Urgent Public Health Need Form
Notification of Importation Form
Page details
-Date modified:
-2025-04-08
+2025-12-05